2.710USD-1.09%Mkt Cap: 543.00M USDP/E: —Last update: 2026-05-22
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a propriet…
Industry Peers
Medical Devices152.25BUSDP/E 24.5
85.88BUSDP/E 24.2
53.45BSEKP/E 22.7
53.33BSEKP/E 98.9
52.13BDKKP/E 22.1
38.61BEURP/E 18.3
23.15BSEK—
22.25BEURP/E 23.4
loading…
Indicators:|
Key Statistics
Company
Market Cap543.00M USD
Enterprise Value566.68M USD
Revenue (TTM)216.56M USD
Gross Profit112.29M USD
Net Income (TTM)-15.63M USD
Revenue/Share1.126 USD
Last Price2.710 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees261
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)Infinity
PEG—
EV/EBITDA-350.67
EV/Revenue2.62
P/S2.54
P/B8.13
EPS (TTM)-0.05
EPS (Forward)0.00
52W Range
1.15078% of range3.150
52W High3.150 USD
52W Low1.150 USD
Profitability
Gross Margin54.47%
Oper. Margin-0.66%
EBITDA Margin-0.75%
Profit Margin-7.58%
ROE-24.33%
ROA-7.04%
Growth
Revenue Growth24.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF4.84M USD
CapEx (TTM)3.73M USD
FCF Margin1.04%
FCF Yield0.42%
Net Debt16.93M USD
Net Debt/EBITDA-10.48
Balance Sheet
Debt/Equity1.51
Current Ratio1.63
Quick Ratio1.02
Book Value/Sh0.3370 USD
Cash/Share0.4010 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.667 USD
Target Range4.000 USD – 5.000 USD
# Analysts3
Ownership
Shares Out.200.37M
Float181.36M
Insiders3.24%
Institutions74.64%
Short Interest
Short Ratio10.8d
Short % Float5.79%
Short % Out.5.63%
Shares Short11.27M
Short (prev mo.)11.12M
Technical
SMA 502.093 (+29.5%)
SMA 2001.875 (+44.5%)
Beta1.63
S&P 52W Chg28.31%
Avg Vol (30d)2.65M
Avg Vol (10d)2.50M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—